InSite Vision — Merger or Acquisition (June 2015)
18 slides from InSite Vision's merger presentation, Jun 10, 2015
Slide 1: InSite Vision Incorporated / QLT Inc. Transaction
Exhibit 99.1 InSite Vision Incorporated / QLT Inc. Transaction June 8, 2015
Slide 2: Cautionary Statement Regarding Forward Looking Statements
Cautionary Statement Regarding Forward Looking Statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition, the expected timetable for completing the transaction, the timetable for and ability of QLT and InSite Vision to make futur
Slide 3: Important Information for Stockholders
Important Information for Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would
Slide 4: Agenda
Agenda Transaction Highlights Transaction Overview Strategic Investments and Distributions The “New” QLT Pipeline Overview & Update Q&A 4
Slide 5: Transaction Highlights
Transaction Highlights Creation of a well-capitalized diversified, pure play, late-stage specialty ophthalmic company Late-stage, diversified ophthalmic pipeline focused on front of the eye and retinal indications - Cash flow generating royalty stream (AzaSite) - BromSite™ NDA to be submitted to FDA
Slide 6: Transaction Highlights
Transaction Highlights Strong cash position/balance sheet Sufficient funding for expected development costs of QLT’s retinoid program and InSite’s lead products Cash flow generating royalty stream (AzaSite) Potential milestones ($16M+) and royalty streams from ROW partnerships AzaSite (NiCox/Europe,
Slide 7: Transaction Overview
Transaction Overview Deal Facts The New QLT New Investors (QLT Acquisition of InSite Vision) All-share transaction at an exchange $20 million new investment from 3 ratio of 0.048x Creates a well-capitalized, pure funds Implies a purchase price per share of play, late-stage specialty ophthalmic Addit
Slide 8: Strategic Investment and Distributions
Strategic Investment and Distributions New QLT to have a cash balance of approximately $70 million - Well funded; strong balance sheet and strategic flexibility New QLT to invest remaining excess cash in concurrently announced strategic investments - QLT to invest $45 million for 9% stake in Aralez
Slide 9: The New QLT at a Glance
The New QLT at a Glance Late-stage specialty ophthalmic company with a diversified pipeline focused on front of the eye and retinal indications Canadian domiciled with headquarters in Vancouver, British Columbia and operations in Alameda, California Listed on both the NASDAQ (QLTI) and TSX (QLT) sto
Slide 10: Diverse Pipeline Supports Near-term and Long-term Growth
Diverse Pipeline Supports Near-term and Long-term Growth Product Category & Indication Clinical Stage Partner Status Patent Life/Exclusivity AzaSite® Antibiotic; Bacterial conjunctivitis Approved: US/Canada Akorn: US & Canada Issued; 2019 Pre-MAA: EU/MEA Nicox: EU/MEA 10-years post-approval Phase 1/
Slide 11: BromSite Overview/Update
BromSiteOverview/Update NDA to be filed promptly with FDA this week Potential “best in class” NSAID Positioning Differentiated label/indication: treatment of inflammation and prevention of pain post-cataract surgery Largest fill volume/bottle size addresses market need/ophthalmologists request Near
Slide 12: DexaSite Overview/Update
DexaSite Overview/Update CMC/Registration lots to be scheduled for manufacturing: 2H 2015 Potential 2016 NDA filing: Treatment of blepharitis Potential first approval for blepharitis DexaSite/AzaSite Plus MAA discussions continue in Europe 12
Slide 13: Ultra-Orphan Phase 3-Ready Retinoid Program (QLT091001)
Ultra-Orphan Phase 3-Ready Retinoid Program (QLT091001) Planned MAA Filing for Conditional Approval by 1H 2016 Planned NDA/MAA Filings for Full Approval by 2018 Orphan Drug designation by both the FDA and EMA for significant unmet medical need $500+ million market potential FDA Fast Trask status for
Slide 14: Retinoid Program Has Achieved Major Milestones
Retinoid Program Has Achieved Major Milestones Pre-study activities underway for the initiation of the Phase 3 pivotal trial by 1H 2016 Includes engaging global study CRO and clinical study sites, IRB submissions and approvals, manufacturing clinical and registration batches Q1 2015 – Meetings held
Slide 15: Retinoid Program Building Momentum on Clinical and Regulatory Fronts in US and EU
Retinoid Program Building Momentum on Clinical and Regulatory Fronts in US and EU Finalized Phase 3 pivotal protocol for US and EU Prospective, multi-center, placebo controlled comparative study of safety and efficacy or oral QLT091001 in subjects with inherited retinal disease phenotypically diagno
Slide 16: Retinoid Product Expected to Achieve First-Line Position
Retinoid Product Expected to Achieve First-Line Position QLT091001 is expected to achieve first-line position in the treatment of inherited retinal diseases caused by mutations in RPE65 or LRAT Currently there are no FDA or EMA approved medicinal treatments for LCA or RP Orphan Drug designated by bo
Slide 17: Transaction Highlights
Transaction Highlights Creation of a well-capitalized diversified, pure play, late-stage specialty ophthalmic company Late-stage, diversified ophthalmic pipeline focused on front of the eye and retinal indications Cash flow generating royalty streams (AzaSite) BromSite™ NDA to be submitted to FDA th
Slide 18: Transaction Highlights
Transaction Highlights Strong cash position/balance sheet Sufficient funding for expected development costs of QLT’s retinoid program and InSite’s lead products Cash flow generating royalty stream (AzaSite) Potential milestones ($16M+) and royalty streams from ROW partnerships AzaSite (NiCox/Europe,